Brief: Aligos Therapeutics Announces Award Of An $8.5 Million Niaid Contract To Advance Development Of Pan-Coronavirus Protease Inhibitor, Alg-097558
03/10/2023 13:11
Oct 3 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ANNOUNCES AWARD OF AN $8.5 MILLION
NIAID
CONTRACT TO ADVANCE DEVELOPMENT OF BEST-IN-CLASS PAN-CORONAVIRUS
PROTEASE INHIBITOR, ALG-097558
* ALIGOS THERAPEUTICS INC - PLANS TO CONTINUE TO SEEK
EXTERNAL
FUNDING TO ADVANCE ALG-097558 BEYOND ONGOING PHASE 1 FIRST IN
HUMAN STUDY
* ALIGOS THERAPEUTICS INC - NIAID CONTRACT WILL SUPPORT
CONDUCTING
NONCLINICAL AND CLINICAL STUDIES TO ADVANCE ALG-097558 INTO
FUTURE PHASE 2/3 STUDIES
Source text for Eikon: ID:nGNX576FHj
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue